Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Crizotinib (Xalkori) - non-small cell lungcancer (NSCLC) 1 crizotinib 200mg and 250mg hard capsules (Xalkori ® ) SMC No 1329/18 Pfizer Limited 4 May 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the ultra-orphan medicine process crizotinib (Xalkori (...) ® ) is accepted for use within NHS Scotland. Indication under review: treatment of adults with ROS1-positive advanced non-small cell lungcancer (NSCLC). In a small, single arm, open-label, phase I study of patients with advanced ROS1-positive NSCLC, treatment with crizotinib resulted in an objective response in 70% of patients. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of crizotinib. This advice is contingent upon the continuing
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous NonSmall-Cell LungCancer 29528793 2018 04 17 1527-7755 36 12 2018 Apr 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese (...) Patients With Advanced Nonsquamous Non‒Small-Cell LungCancer. 1207-1217 10.1200/JCO.2017.76.7145 Purpose Patients with advanced non‒small-cell lungcancer (NSCLC) who fail two lines of chemotherapy have unmet medical needs. The kinase inhibitor fruquintinib selectively targets vascular endothelial growth factor receptors and, hence, tumor angiogenesis and lymphogenesis. This randomized, double-blind, placebo-controlled, multicenter phase II trial evaluated the efficacy and safety of fruquintinib
Risk factors for disseminated intravascular coagulation in patients with lungcancer 29851300 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Risk factors for disseminated intravascular coagulation in patients with lungcancer. 931-938 10.1111/1759-7714.12766 The mortality rate from disseminated intravascular coagulation (DIC) is higher in patients with lungcancer than in non-lungcancer patients. Moreover, the prevalence of DIC varies among the pathologic types of lungcancer (...) . This study analyzed the relationship between coagulation factors and the pathologic types of lungcancer. Twenty-six patients with progressive, inoperable stage IIB or higher lungcancer (20 men, 6 women; mean age 71 years; 11 Adeno, 10 squamous cell carcinoma, and 5 small cell carcinoma) and five healthy volunteers without respiratory disease (3 men, 2 women; mean age 72 years) were enrolled in the study. Blood samples were collected at lungcancer diagnosis, before treatment. White blood cell count
Identifying Patients for Whom LungCancer Screening is Preference-Sensitive: A Microsimulation Study. Background: Many health systems are exploring how to implement low-dose computed tomography (LDCT) screening programs that are effective and patient-centered. Objective: To examine factors that influence when LDCT screening is preference-sensitive. Design: State-transition microsimulation model. Data Sources: Two large randomized trials, published decision analyses, and the SEER (Surveillance (...) , Epidemiology, and End Results) cancer registry. Target Population: U.S.-representative sample of simulated patients meeting current U.S. Preventive Services Task Force criteria for screening eligibility. Time Horizon: Lifetime. Perspective: Individual. Intervention: LDCT screening annually for 3 years. Outcome Measures: Lifetime quality-adjusted life-year gains and reduction in lungcancer mortality. To examine the effect of preferences on net benefit, disutilities (the "degree of dislike") quantifying
Intronic variant of EGFR is associated with GBAS expression and survival outcome of earlyâ€stage nonâ€small cell lungcancer 29806744 2018 11 14 1759-7714 9 8 2018 Aug Thoracic cancer Thorac Cancer Intronic variant of EGFR is associated with GBAS expression and survival outcome of early-stage non-small cell lungcancer. 916-923 10.1111/1759-7714.12757 Genome-wide association studies have indicated that most of the currently identified disease and trait-associated single nucleotide (...) polymorphisms (SNPs) are intronic or intergenic. RegulomeDB is a recently developed database that provides functional annotations for regulatory features of SNPs located in non-coding regions. We evaluated the potential regulatory SNPs in the EGFR gene region using RegulomeDB and their associations with prognosis after surgery in non-small cell lungcancer (NSCLC) patients. A total of 698 patients with surgically resected NSCLC were enrolled and seven SNPs were selected based on the RegulomeDB database. All
Higher LungCancer Incidence in Young Women Than Young Men in the United States. BACKGROUND: Previous studies showed a higher incidence of lungcancer among young women than among young men in the United States. Whether this pattern has continued in contemporary birth cohorts and, if so, whether it can be fully explained by sex differences in smoking behaviors are unknown. METHODS: We examined the nationwide population-based incidence of lungcancer according to sex, race or ethnic group, age (...) group (30 to 34, 35 to 39, 40 to 44, 45 to 49, and 50 to 54 years), year of birth (1945 to 1980), and calendar period of diagnosis (1995-1999, 2000-2004, 2005-2009, and 2010-2014), and we calculated female-to-male incidence rate ratios. We also examined the prevalence of cigarette smoking, using data from the National Health Interview Survey from 1970 to 2016. RESULTS: Over the past two decades, the age-specific incidence of lungcancer has generally decreased among both men and women 30 to 54 years
Efficacy and safety of nivolumab in nonâ€small cell lungcancer with preexisting interstitial lung disease 29782069 2018 11 14 1759-7714 9 7 2018 Jul Thoracic cancer Thorac Cancer Efficacy and safety of nivolumab in non-small cell lungcancer with preexisting interstitial lung disease. 847-855 10.1111/1759-7714.12759 The risk of developing lungcancer is high in patients with interstitial lung disease (ILD), as few treatment options are available. Immune checkpoint inhibitors (ICI) are used (...) for the treatment of non-small cell lungcancer (NSCLC) in clinical practice; however, in patients with preexisting ILD, the risk of ICI-related pneumonitis is unknown. We evaluated the efficacy and lung toxicity of nivolumab in patients with NSCLC and ILD. We retrospectively reviewed the medical records of 216 NSCLC patients who had received nivolumab therapy. The existence of ILD in these patients was determined by lung computed tomography findings; 26 patients had ILD. We evaluated the efficacy of nivolumab
Magnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lungcancer patients after radiotherapy: A preliminary study 29774659 2018 11 14 1759-7714 9 7 2018 Jul Thoracic cancer Thorac Cancer Magnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lungcancer patients after radiotherapy: A preliminary study. 865-873 10.1111/1759-7714.12763 This study used magnetic resonance imaging (MRI) to monitor changes (...) to brain metastases and investigate the imaging signs used to evaluate treatment efficacy and determine prognosis following radiotherapy for brain metastases from lungcancer. A total of 60 non-small cell lungcancer patients with brain oligometastases were selected. MRI scans were conducted before and 3, 6, 9, 12, 18, 24, and 30 months after radiotherapy. The tumor and peritumoral edema diameters, Cho/Cr values, elevation of the Lip peak value, and whether the island (yu-yuan) sign or high-signal ring
Comparison and discussion of the treatment guidelines for small cell lungcancer 29770597 2018 11 14 1759-7714 9 7 2018 Jul Thoracic cancer Thorac Cancer Comparison and discussion of the treatment guidelines for small cell lungcancer. 769-774 10.1111/1759-7714.12765 Small cell lungcancer (SCLC), which accounts for 15% to 17% of all lungcancers, is one of the leading causes of cancer-related death worldwide. More than 130 000 new diagnoses of SCLC and 100 000 deaths from the disease were (...) estimated to have occurred in China in 2013. The existing guidelines of SCLC therapeutic principles differ by region. In recent years, new immunotherapy and targeted therapy treatments have been lacking. In order to understand the current status of SCLC treatment in more detail, we identified the similarities and differences among the latest National Comprehensive Cancer Network Clinical Practice Guidelines for SCLC, the Chinese Society of Clinical Oncology LungCancer Guidelines, and the European
Real world study of regimen containing bevacizumab as firstâ€line therapy in Chinese patients with advanced nonâ€small cell lungcancer 29768721 2018 11 14 1759-7714 9 7 2018 Jul Thoracic cancer Thorac Cancer Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lungcancer. 805-813 10.1111/1759-7714.12650 Large scale randomized controlled trials have demonstrated that the use of bevacizumab in addition to chemotherapy (...) in patients with advanced non-small cell lungcancer (NSCLC) conveys significant survival benefits. We explored the clinical impact of a first-line regimen containing bevacizumab (B+) versus a non-bevacizumab regimen (non-B) in advanced non-squamous NSCLC (NS-NSCLC) patients in a real world setting. The medical records of patients with advanced NS-NSCLC who received first-line therapy with or without bevacizumab were retrospectively collected. The primary outcome was progression-free survival (PFS
Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis 29766649 2018 11 14 1759-7714 9 7 2018 Jul Thoracic cancer Thorac Cancer Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis. 785-793 10.1111/1759-7714.12645 Colorectal cancer (CRC) is a common and lethal disease in which distant metastasis remains the primary cause of death. Paradoxical roles of LOX have been reported in CRC, and the intracellular function of LOX has also recently been (...) or TEAD4 short hairpin RNA interference in a LoVo cell line. LOX messenger RNA expression was elevated in some CRC specimens, and LOX nuclear localization was detected in CRC tumor tissues. LOX nuclear localization was found to correlate with lung/hepatic metastasis, elevated serum carcinoembryonic antigen concentration, and mucinous tumor type (P < 0.05). Nuclear LOX expression was found to be associated with poor overall and disease-free survival (P < 0.05), and postoperative lung/hepatic metastasis
Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography LungCancer Screening. Background: Lungcancer screening guidelines recommend using individualized risk models to refer ever-smokers for screening. However, different models select different screening populations. The performance of each model in selecting ever-smokers for screening is unknown. Objective: To compare the U.S. screening populations selected by 9 lungcancer risk models (the Bach model (...) ; the Spitz model; the Liverpool Lung Project [LLP] model; the LLP Incidence Risk Model [LLPi]; the Hoggart model; the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 [PLCOM2012]; the Pittsburgh Predictor; the LungCancer Risk Assessment Tool [LCRAT]; and the LungCancer Death Risk Assessment Tool [LCDRAT]) and to examine their predictive performance in 2 cohorts. Design: Population-based prospective studies. Setting: United States. Participants: Models selected U.S. screening
Feasibility of reâ€biopsy and EGFR mutation analysis in patients with nonâ€small cell lungcancer 29761660 2018 11 14 1759-7714 9 7 2018 Jul Thoracic cancer Thorac Cancer Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lungcancer. 856-864 10.1111/1759-7714.12762 In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy (...) is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lungcancer (NSCLC) patients in real-world clinical practice. We retrospectively reviewed the clinical and pathologic data of advanced NSCLC patients who experienced disease progression after previous treatment with EGFR-TKIs at a single tertiary hospital in Korea between January 2014 and December 2016. Re-biopsy specimens included small biopsy, surgical tissue, or liquid-based cytology. EGFR
Stage III Nonâ€“Small-Cell LungCancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort 30241276 2018 12 07 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Stage III Non-Small-Cell LungCancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort. 1-11 10.1200/JGO.17.00214 Of newly diagnosed patients (...) with non-small-cell lungcancer (NSCLC), stage III accounts for 30%. Most patients are treated with concurrent chemoradiation therapy, but the addition of consolidation chemotherapy (CC) is debatable. We examined the effect of CC in Brazilian patients with stage III NSCLC treated in routine clinical practice. We retrospectively collected data for patients from five different Brazilian cancer institutions who had stage III NSCLC and who were treated with chemoradiation therapy followed or not by CC